$695 | Single User
$1395 | Global License

Physician Views: Anti-CGRP mAbs looking to shake up migraine prevention – how and where will they fit in?
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 01 May 2015 | 227 | In Stock
Related Topics: Boehringer Ingelheim , Drug , FDA , Lilly



Drugmakers may finally have cracked the code to developing safe and effective inhibitors of the calcitonin gene-related peptide (CGRP), a neuropeptide long believed to be associated with migraine headaches but which had proven exceedingly difficult to target with pharmaceuticals.

As it turns out, the key was moving on from small molecules, where companies like Boehringer Ingelheim and Merck & Co. ran into problems with off-target liver toxicities, and taking advantage of the highly specific nature of monoclonal antibodies. Four companies – Alder, Amgen, Eli Lilly and Teva – have recently reported Phase II results for mAbs candidates that are so far living up to the hype. (See ViewPoints: New data suggest the anti-CGRP race is closer than once thought.)

Cross-study comparisons of the products are fraught with difficulties given the highly variable and important differences in baseline characteristics, but Morgan Stanley analyst Matthew Harrison said that “in general, the placebo-adjusted responses are comparable across agents with an one-day reduction in mean migraine days and a roughly 10-percent to 25-percent increase in 50-percent responder rate.”

The most obvious differentiator among the four programmes is their target as Alder, Eli Lilly and Teva are developing mAbs that hit the CGRP ligand while Amgen’s AMG 334 binds directly to the CGRP receptor. Bernstein analyst Geoff Porges notes Amgen has floated the possibility that its approach may offer certain efficacy and/or dosing advantages over ligand-directed products, however, these have yet to emerge.

In fact, the opposite may turn out to be true when it comes to dosing as AMG 334’s short half-life (potentially a result of targeting of the CGRP receptor directly) may put it at a disadvantage to other products on dosing, particularly Alder’s ALD403, which has a half-life of 26 days and is expected to be dosed quarterly. AMG 334’s half-life is estimated at only 11 days, meaning it is likely to require monthly dosing. Eli Lilly’s LY2951742 and Teva’s TEV-48125 are testing monthly dosing schedules as well at the moment. Dosing is not a clear victory for Alder, however, as its ALD403 is only available – for the time being anyway – for intravenous delivery, whereas the other three agents can be self-administered subcutaneously.

Unlike its three competitors, which have only reported data in patients with episodic migraines, Teva’s TEV-48125 is the only agent that has generated data in the all-important chronic migraine setting, a distinction that Porges said could give the Israeli drugmaker a potential leg up. (See ViewPoints: Handicapping the four-horse race among anti-CGRP mAbs for migraine.)

Patients, physicians, payers and investors will be watching the progress being made with anti-CGRP mAbs closely as there is a clear unmet need for safe and effective prophylactic therapies for high-frequency episodic and chronic migraines, which is a market that Cowen analyst Eric Schmidt believes could represent a multi-billion dollar opportunity for products that pass regulatory muster. And no wonder given estimate from the US Centers for Disease Control that more than 14 percent of adults have experienced a migraine or severe headache in the past three months.

Preventative therapy for patients with episodic migraines involves some combination of antihypertensives, antiepileptics and antidepressants, often supplemented by acute rescue medications like triptans. Recently, Botox (botulinum toxin A) from Actavis became the first FDA-approved prophylactic product for chronic migraines and, while it is not indicated for episodic migraines, it has become the go-to agent in this setting for many doctors, according to UBS analyst Marc Goodman. Also in the mix is STX-Med’s Cefaly, a transcutaneous electrical nerve stimulation (TENS) device that last year became the first device to be approved in the US for migraines.

Puchase Reasons

Given the complex treatment environment into which the anti-CGRP mAbs are heading towards, characterised by the large unmet need and highly variable nature of the management and responses from patients with episodic or chronic migraines, FirstWord PLUS commissioned a poll of neurologists and primary care physicians in the US and EU5. To gain a better understanding of how they see the new class of migraine prophylactic fitting in, as well as what factors might help set individual products apart from the rest, the questions they are being asked include…

  • What drug(s) do you tend to prescribe for the prevention of high-frequency episodic migraines (defined as fewer than 15 migraine days per month)?

  • In patients with (high-frequency) episodic migraines, preliminary Phase II data for several anti-CGRP mAbs showed roughly a 1-day reduction in mean migraine days per month and 10% to 25% improvement in 50%-responder rates. If anti-CGRP mAbs are eventually approved based on similar data, which would you be more likely to prescribe first to prevent episodic migraines?

  • In patients with chronic migraines (defined as more than 15 migraine days per month), preliminary Phase II data for one anti-CGRP mAb showed 50%-responder rates of greater than 50%, rapid onset and lower consumption of acute migraine medications. If this product and/or others from the CGRP class are approved based on similar data, which would you be more likely to prescribe first to prevent chronic migraines?

  • If multiple anti-CGRP mAbs are approved at roughly the same time based on comparable safety and efficacy data, what other factors will be most important when you decide which drug to prescribe?

  • For patients with moderate to severe migraines, would you be more likely to prescribe a subcutaneous drug that is dosed monthly or an intravenous drug that is dosed quarterly?
  • Table of Contents
    for Physician Views: Anti-CGRP mAbs looking to shake up migraine prevention – how and where will they fit in?

    Additional Details


    FirstWord Pharma

    Publisher Information


    227 |

    Report Format


    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Anti-CGRP mAbs looking to shake up migraine prevention – how and where will they fit in? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types


    Buy now using our secure payment system.

    We Stock...